Major Companies for Therapeutic Monoclonal Antibodies Market: AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine.
Global Therapeutic Monoclonal Antibodies Market Size was estimated at USD 34740 million in 2022 and is projected to reach USD 42457.3659081159 million by 2028, exhibiting a CAGR of 3.4% during the forecast period.
Global Therapeutic Monoclonal Antibodies Market Overview And Scope:
The Global Therapeutic Monoclonal Antibodies Market Report 2024 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Therapeutic Monoclonal Antibodies utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2024 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Therapeutic Monoclonal Antibodies Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Therapeutic Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Therapeutic Monoclonal Antibodies market.
Global Therapeutic Monoclonal Antibodies Market Segmentation
By Type, Therapeutic Monoclonal Antibodies market has been segmented into:
Mouse-derived Antibodies
Chimeric Antibodies
Humanized Antibodies
By Application, Therapeutic Monoclonal Antibodies market has been segmented into:
Immune Diseases
Cancer
Other
Regional Analysis of Therapeutic Monoclonal Antibodies Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Therapeutic Monoclonal Antibodies Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Therapeutic Monoclonal Antibodies market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Therapeutic Monoclonal Antibodies market.
Major Companies Covered in Therapeutic Monoclonal Antibodies market are:
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
Regeneron
Innovent
Hengrui Medicine
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Therapeutic Monoclonal Antibodies Market by Type
5.1 Therapeutic Monoclonal Antibodies Market Overview Snapshot and Growth Engine
5.2 Therapeutic Monoclonal Antibodies Market Overview
5.3 Mouse-derived Antibodies
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Mouse-derived Antibodies: Geographic Segmentation
5.4 Chimeric Antibodies
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Chimeric Antibodies: Geographic Segmentation
5.5 Humanized Antibodies
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Humanized Antibodies: Geographic Segmentation
Chapter 6: Therapeutic Monoclonal Antibodies Market by Application
6.1 Therapeutic Monoclonal Antibodies Market Overview Snapshot and Growth Engine
6.2 Therapeutic Monoclonal Antibodies Market Overview
6.3 Immune Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Immune Diseases: Geographic Segmentation
6.4 Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Cancer: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Therapeutic Monoclonal Antibodies Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Therapeutic Monoclonal Antibodies Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Therapeutic Monoclonal Antibodies Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ABBVIE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 JOHNSON & JOHNSON
7.4 NOVARTIS
7.5 GILEAD SCIENCES
7.6 ROCHE
7.7 BRISTOL-MYERS SQUIBB
7.8 AMGEN
7.9 ASTRAZENECA
7.10 MERCK & CO
7.11 TAKEDA
7.12 MERCK KGAA
7.13 SEAGEN
7.14 ELI LILLY
7.15 ONO PHARMACEUTICAL
7.16 PFIZER
7.17 REGENERON
7.18 INNOVENT
7.19 HENGRUI MEDICINE
Chapter 8: Global Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Mouse-derived Antibodies
8.2.2 Chimeric Antibodies
8.2.3 Humanized Antibodies
8.3 Historic and Forecasted Market Size By Application
8.3.1 Immune Diseases
8.3.2 Cancer
8.3.3 Other
Chapter 9: North America Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Mouse-derived Antibodies
9.4.2 Chimeric Antibodies
9.4.3 Humanized Antibodies
9.5 Historic and Forecasted Market Size By Application
9.5.1 Immune Diseases
9.5.2 Cancer
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Mouse-derived Antibodies
10.4.2 Chimeric Antibodies
10.4.3 Humanized Antibodies
10.5 Historic and Forecasted Market Size By Application
10.5.1 Immune Diseases
10.5.2 Cancer
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Mouse-derived Antibodies
11.4.2 Chimeric Antibodies
11.4.3 Humanized Antibodies
11.5 Historic and Forecasted Market Size By Application
11.5.1 Immune Diseases
11.5.2 Cancer
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Mouse-derived Antibodies
12.4.2 Chimeric Antibodies
12.4.3 Humanized Antibodies
12.5 Historic and Forecasted Market Size By Application
12.5.1 Immune Diseases
12.5.2 Cancer
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Mouse-derived Antibodies
13.4.2 Chimeric Antibodies
13.4.3 Humanized Antibodies
13.5 Historic and Forecasted Market Size By Application
13.5.1 Immune Diseases
13.5.2 Cancer
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Therapeutic Monoclonal Antibodies Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Mouse-derived Antibodies
14.4.2 Chimeric Antibodies
14.4.3 Humanized Antibodies
14.5 Historic and Forecasted Market Size By Application
14.5.1 Immune Diseases
14.5.2 Cancer
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Therapeutic Monoclonal Antibodies Scope:
Report Data
|
Therapeutic Monoclonal Antibodies Market
|
Therapeutic Monoclonal Antibodies Market Size in 2022
|
USD 34740 million
|
Therapeutic Monoclonal Antibodies CAGR 2023 - 2030
|
3.4%
|
Therapeutic Monoclonal Antibodies Base Year
|
2022
|
Therapeutic Monoclonal Antibodies Forecast Data
|
2023 - 2030
|
Segments Covered
|
By Type, By Application, And by Regions
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
Key Companies Profiled
|
AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine.
|
Key Segments
|
By Type
Mouse-derived Antibodies Chimeric Antibodies Humanized Antibodies
By Applications
Immune Diseases Cancer Other
|